These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17785201)

  • 1. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative.
    Peggs KS; Segal NH; Allison JP
    Cancer Cell; 2007 Sep; 12(3):192-9. PubMed ID: 17785201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
    Baxevanis CN; Perez SA; Papamichail M
    Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From cancer immunosurveillance to cancer immunotherapy.
    Stagg J; Johnstone RW; Smyth MJ
    Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies to improve tumor immunotherapy.
    Begley J; Ribas A
    Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.
    Greiner J; Schmitt M
    Eur J Haematol; 2008 Jun; 80(6):461-8. PubMed ID: 18284627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
    Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
    Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for the use of NK cells in immunotherapy of human cancer.
    Ljunggren HG; Malmberg KJ
    Nat Rev Immunol; 2007 May; 7(5):329-39. PubMed ID: 17438573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenic anti-cancer chemotherapy as an emerging concept.
    Haynes NM; van der Most RG; Lake RA; Smyth MJ
    Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies in clinical hematology and oncology.
    Nagorsen D; Thiel E
    Curr Opin Investig Drugs; 2007 Dec; 8(12):996-1001. PubMed ID: 18058570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging the immune response to monitor tumor immunotherapy.
    Wang Q; Ornstein M; Kaufman HL
    Expert Rev Vaccines; 2009 Oct; 8(10):1427-37. PubMed ID: 19803763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New frontiers in cell-based immunotherapy of cancer.
    D'Elios MM; Del Prete G; Amedei A
    Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.